Carlsmed Leads Surgical Instruments Peers in Potential Upside

Got story updates? Submit your updates here. ›

Carlsmed (NASDAQ:CARL) is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions. The company's aprevo Technology Platform, consisting of AI-powered software, custom-designed interbody implants, and single-use surgical instruments, aims to address the limitations of traditional spine fusion surgery and improve patient outcomes. Carlsmed's peers in the 'Surgical, Medical, And Dental Instruments And Supplies' industry have higher revenue and earnings, but Carlsmed is trading at a lower price-to-earnings ratio, indicating it is more affordable. Analysts believe Carlsmed has higher potential upside compared to its peers.

Why it matters

Carlsmed's personalized spine surgery solutions using AI and custom implants could disrupt the traditional spine fusion market, which has been plagued by high revision rates and poor outcomes. If successful, Carlsmed's technology could improve patient care and reduce the significant economic burden of revision surgeries on the healthcare system.

The details

Carlsmed's aprevo Technology Platform utilizes AI-enabled software, custom-designed interbody implants, and single-use surgical instruments to provide personalized surgical plans and implants for each patient's unique anatomy. This aims to address the limitations of traditional spine fusion surgery, which often lacks robust pre-operative planning and uses one-size-fits-all implants that fail to match patient anatomy, leading to poor alignment and higher revision rates. Carlsmed's technology is 510(k) cleared by the FDA for lumbar interbody fusion surgeries and the company is developing it for cervical fusion as well.

• In November 2024, Carlsmed received FDA 510(k) clearance for its aprevo interbody implants for cervical interbody fusion surgeries.
• In 2025, Carlsmed plans to continue building its aprevo Technology Platform for cervical fusion procedures by pursuing additional clearances for advancements to its cervical software platform and personalized plating solutions.
• Carlsmed expects to commercialize the aprevo Technology Platform for cervical fusion surgery in 2026, assuming it receives the necessary additional clearances.

What’s next

Carlsmed plans to continue growing its commercial infrastructure, including its direct sales team and number of independent sales agents, as well as expand various market access initiatives to drive further adoption of its aprevo Technology Platform.